Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

The deal reflects Nordic’s bet on artificial-intelligence advancements in healthcare.

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its ...

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

The stock's fall snapped a four-day winning streak.

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

According to Benzinga Pro, Merck & Co's peer group average for short interest as a percentage of float is 3.74%, which means ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from ...

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.

US pharma giant Merck & Co today revealed that the US Food and Drug Administration (FDA) has accepted and granted priority ...